



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



Treprostinil-d₉

Cat. No.:	HY-100441S2		
CAS No.:	2747918-14-3		
Molecular Formula:	C ₂₃ H ₂₅ D ₉ O ₅		
Molecular Weight:	399.57		
Target:	Isotope-Labeled Compounds		
Pathway:	Others		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (312.84 mM; Need ultrasonic and warming)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.5027 mL	12.5135 mL	25.0269 mL
	5 mM		0.5005 mL	2.5027 mL	5.0054 mL
	10 mM		0.2503 mL	1.2513 mL	2.5027 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description	Treprostinil-d ₉ (UT-15-d ₉) is the deuterium-labeled Treprostinil (HY-100441) ^[1] . Treprostinil (UT-15) is a potent DP1 and EP2 agonist with EC ₅₀ values of 0.6±0.1 and 6.2±1.2 nM, respectively.
IC ₅₀ & Target	EC ₅₀ : 0.6±0.1 nM (DP1), 6.2±1.2 nM (EP2) ^[1]
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA